Position in ATHE
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$10,004
+$3,521 QoQ
Shares Held
1,863
0.0% QoQ
Ownership
0.010%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#10
of 22 holders
Holding Since
Sep 2025
4 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ATHE Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026ACADIAN ASSET MANAGEMENT LLC holds $731,256,203 across 167 Biotechnology names. ATHE ranks #160 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | INCY |
Incyte Corp
|
1,664,999 | $188,744,286 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
157,440 | $98,170,137 | |
| 3 | IMCR |
Immunocore Holdings plc
|
1,209,894 | $38,414,134 | |
| 4 | RIGL |
Rigel Pharmaceuticals Inc
|
591,686 | $23,146,756 | |
| 5 | EXEL |
Exelixis, Inc.
|
421,444 | $22,930,768 | |
| 6 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
42,122 | $20,923,261 | |
| 7 | TBPH |
Theravance Biopharma, Inc.
|
1,174,910 | $19,973,470 | |
| 8 | PRTA |
Prothena Corp Public Ltd Co
|
2,010,645 | $19,684,214 |
All Filings in ATHE
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $10,004 | 1,863 | Shares | Defined | 2026-08-13 | |
| 2026-03-31 | $6,483 | 1,863 | Shares | Defined | 2026-05-13 | |
| 2025-12-31 | $14,780 | 4,799 | Shares | Defined | 2026-02-10 | |
| 2025-09-30 | $18,044 | 4,799 | Shares | Defined | 2025-11-13 | |
| No filing history on record for this holder in this stock. | ||||||